Role of RACK1 in the differential proliferative effects of neuropeptide Y1-36 and peptide YY1-36 in SHR vs. WKY preglomerular vascular smooth muscle cells

American Journal of Physiology - Renal Physiology

Volumn 304, Issue 6, 2013, Pages

  Cheng, Dongmei ^a   Zhu, Xiao ^a   Gillespie, Delbert G ^a   Jackson, Edwin K ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cell proliferation; Preglomerular vascular smooth muscle cells; Receptor for activated C kinase 1; Spontaneously hypertensive rats; Wistar kyoto rats

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; NEUROPEPTIDE Y; PEPTIDE YY; PHOSPHOLIPASE C; RECEPTOR FOR ACTIVATED C KINASE 1; SMALL INTERFERING RNA; GUANINE NUCLEOTIDE BINDING PROTEIN; HETEROTRIMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; PROTEIN KINASE C; RACK1 PROTEIN, RAT; THYMIDINE; TRITIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL FRACTIONATION; CELL MEMBRANE; CELL PROLIFERATION; CONTROLLED STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RAT; SMOOTH MUSCLE FIBER; SPONTANEOUSLY HYPERTENSIVE RAT; VASCULAR SMOOTH MUSCLE; VASCULAR SMOOTH MUSCLE CELL; WESTERN BLOTTING; WISTAR KYOTO RAT; ANIMAL; COMPARATIVE STUDY; CYTOLOGY; KIDNEY; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; VASCULARIZATION;

ANIMALS; CELL PROLIFERATION; GTP-BINDING PROTEINS; HETEROTRIMERIC GTP-BINDING PROTEINS; KIDNEY; MALE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NEUROPEPTIDE Y; PEPTIDE YY; PLASMIDS; PROTEIN KINASE C; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; THYMIDINE; TRITIUM; TYPE C PHOSPHOLIPASES;

MLCS; MLOWN;

EID: 84877930367     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00646.2012     Document Type: Article

References (61)

1. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 270: 27489-27494, 1995.
2. Ambasta RK, Ai X, Emerson CP Jr. Quail Sulf1 function requires asparagine-linked glycosylation. J Biol Chem 282: 34492-34499, 2007.
3. Anini Y, Fu-Cheng X, Cuber JC, Kervran A, Chariot J, Roz C. Comparison of the postprandial release of peptide YY and proglucagon-derived peptides in the rat. Pflügers Arch 438: 299-306, 1999.
4. Armstrong DN, Ballantyne GH, Adrian TE, Bilchik AJ, McMillen MA, Modlin IM. Adaptive increase in peptide YY and enteroglucagon after proctocolectomy and pelvic ileal reservoir construction. Dis Colon Rectum 34: 119-125, 1991.
5. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 60: 1454-1470, 2006.
6. Berglund MM, Hipskind PA, Gehlert DR. Recent developments in our understanding of the physiological role of PP-fold peptide receptor subtypes. Exp Biol Med 228: 217-244, 2003.
7. Bleasdale JE, Thakur NR, Gremban RS, Bundy GL, Fitzpatrick FA, Smith RJ, Bunting S. Selective inhibition of receptor-coupled phospho-lipase C-dependent processes in human platelets and polymorphonuclear neutrophils. J Pharmacol Exp Ther 255: 756-768, 1990.
8. Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension 54: 516-523, 2009.
9. Carpenter CL, Cantley LC. Phosphoinositide kinases. Curr Opin Cell Biol 8: 153-158, 1996.
10. Chen S, Spiegelberg BD, Lin F, Dell EJ, Hamm HE. Interaction of Gbetagamma with RACK1 and other WD40 repeat proteins. J Mol Cell Cardiol 37: 399-406, 2004.
11. Cheng D, Zhu X, Barchiesi F, Gillespie DG, Dubey RK, Jackson EK. Receptor for activated protein kinase C1 regulates cell proliferation by modulating calcium signaling. Hypertension 58: 689-695, 2011.
12. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351: 95-105, 2000.
13. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev 77: 75-197, 1997.
14. Dopie J, Skarp KP, Rajakyla EK, Tanhuanpaa K, Vartiainen MK. Active maintenance of nuclear actin by importin 9 supports transcription. Proc Natl Acad Sci USA 109: E544-E552, 2012.
15. Dubinion JH, Mi Z, Zhu C, Gao L, Jackson EK. Pancreatic polypep-tide-fold peptide receptors and angiotensin II-induced renal vasoconstric-tion. Hypertension 47: 545-551, 2006.
16. Esler M, Lambert G, Brunner-La Rocca HP, Vaddadi G, Kaye D. Sympathetic nerve activity and neurotransmitter release in humans: translation from pathophysiology into clinical practice. Acta Physiol Scand 177: 275-284, 2003.
17. Esler M, Rumantir M, Wiesner G, Kaye D, Hastings J, Lambert G. Sympathetic nervous system and insulin resistance: from obesity to diabetes. Am J Hypertens 14: 304S-309S, 2001.
18. Freire RD, Cardoso MA, Gimeno SGA, Ferreira SR, Japanese-Brazilian Diabetes Study. Dietary fat is associated with metabolic syndrome in Japanese Brazilians. Diabetes Care 28: 1779-1785, 2005.
19. Fu-Cheng X, Anini Y, Chariot J, Castex N, Galmiche JP, Roze C. Mechanisms of peptide YY release induced by an intraduodenal meal in rats: neural regulation by proximal gut. Pflügers Arch 433: 571-579, 1997.
20. Gorrell MD. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci 108: 277-292, 2005.
21. Grouzmann E, Livio F, Buclin T. Angiotensin-converting enzyme and dipeptidyl peptidase IV inhibitors: an increased risk of angioedema. Hypertension 54: 468-470, 2009.
22. Haefliger JA, Waeber B, Grouzmann E, Braissant O, Nussberger J, Nicod P, Waeber G. Cellular localization, expression and regulation of neuropeptide Y in kidneys of hypertensive rats. Regul Pept 82: 35-43, 1999.
23. Hanke JH, Gardner JP, Dow RL, Changelian PS, Brissette WH, Weringer EJ, Pollok BA, Connelly PA. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T-cell activation. J Biol Chem 271: 695-701, 1996.
24. Huang S, Bjornsti MA, Houghton PJ. Rapamycins: mechanism of action and cellular resistance. Cancer Biol Ther 2: 222-232, 2003.
25. Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, Imamura M, Aoki T, Etoh T, Hashimoto T, Naruse M, Sano H, Utsumi H, Nawata H. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 49: 1939-1945, 2000.
26. Jackson EK, Kochanek SJ, Gillespie DG. Dipeptidyl peptidase IV regulates proliferation of preglomerular vascular smooth muscle and mesangial cells. Hypertension 60: 757-764, 2012.
27. Kirino Y, Sato Y, Kamimoto T, Kawazoe K, Minakuchi K, Nakahori Y. Interrelationship of dipeptidyl peptidase IV (DPP IV) with the development of diabetes, dyslipidaemia and nephropathy: A streptozotocin-induced model using wild-type and DPP IV-deficient rats. J Endocrinol 200: 53-61, 2008.
28. Korner J, Bessler M, Cirilo LJ, Conwell IM, Daud A, Restuccia NL, Wardlaw SL. Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J Clin Endocrinol Metab 90: 359-365, 2005.
29. Ku WC, Cheng AJ, Wang TC. Inhibition of telomerase activity by PKC inhibitors in human nasopharyngeal cancer cells in culture. Biochem Biophys Res Commun 241: 730-736, 1997.
30. Lestner JM, Baburaj R, Edwards CMB. Renal impairment with sita-gliptin: is there a need for active monitoring of potential renal toxicity? Br J Hosp Med 72: 412-413, 2011.
31. Li J, Guo Y, Feng X, Wang Z, Wang Y, Deng P, Zhang D, Wang R, Xie L, Xu X, Zhou Y, Ji N, Hu J, Zhou M, Liao G, Geng N, Jiang L, Wang Z, Chen Q. Receptor for activated C kinase 1 (RACK1): a regulator for migration and invasion in oral squamous cell carcinoma cells. J Cancer Res Clin Oncol 138: 563-571, 2012.
32. Li W, Febbraio M, Reddy SP, Yu DY, Yamamoto M, Silverstein RL. CD36 participates in a signaling pathway that regulates ROS formation in murine VSMCs. J Clin Invest 120: 3996-4006, 2010.
33. Liu YV, Hubbi ME, Pan F, McDonald KR, Mansharamani M, Cole RN, Liu JO, Semenza GL. Calcineurin promotes hypoxia-inducible factor 1a expression by dephosphorylating RACK1 and blocking RACK1 dimerization. J Biol Chem 282: 37064-37073.
34. MacIntosh CG, Andrews JM, Jones KL, Wishart JM, Morris HA, Jansen JB, Morley JE, Horowitz M, Chapman IM. Effects of age on concentrations of plasma cholecystokinin, glucagon-like peptide 1, and peptide YY and their relation to appetite and pyloric motility. Am J Clin Nutr 69: 999-1006, 1999.
35. McIntosh CH, Demuth HU, Pospisilik JA, Pederson R. Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents? Regul Pept 128: 159-165, 2005.
36. Melanson EL, Astrup A, Donahoo WT. The relationship between dietary fat and fatty acid intake and body weight, diabetes, and the metabolic syndrome. Ann Nutr Metab 55: 229-243, 2009.
37. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 85: 9-24, 1999.
38. Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Lar-hammar D, Quirion R, Schwartz T, Westfall TXVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol Rev 50: 143-150, 1998.
39. Mokkapatti R, Vyas SJ, Romero GG, Mi Z, Inoue T, Dubey RK, Gillespie DG, Stout AK, Jackson EK. Modulation by angiotensin II of isoproterenol-induced cAMP production in preglomerular microvascular smooth muscle cells from normotensive and genetically hypertensive rats. J Pharmacol Exp Ther 287: 223-231, 1998.
40. Moyers JS, Bouton AH, Parsons SJ. The sites of phosphorylation by protein kinase C and an intact SH2 domain are required for the enhanced response to beta-adrenergic agonists in cells overexpressing c-src. Mol Cell Biol 13: 2391-2400, 1993.
41. Myklebust LM, Akslen LA, Varhaug JE, Lillehaug JR. Receptor for activated protein C kinase 1 (RACK1) is overexpressed in papillary thyroid carcinoma. Thyroid 21: 1217-1225, 2011.
42. Newton AC. Protein kinase C: structure, function, and regulation. J Biol Chem 270: 28495-28498, 1995.
43. Ohnishi T, Ohba H, Seo KC, Im J, Sato Y, Iwayama Y, Furuichi T, Chung SK, Yoshikawa T. Spatial expression patterns and biochemical properties distinguish a second myo-inositol monophosphatase IMPA2 from IMPA1. J Biol Chem 282: 637-646, 2007.
44. Pappas TN, Debas HT, Chang AM, Taylor IL. Peptide YY release by fatty acids is sufficient to inhibit gastric emptying in dogs. Gastroenterology 91: 1386-1389, 1986.
45. Riccardi G, Giacco R, Rivellese AA. Dietary fat, insulin sensitivity and the metabolic syndrome. Clin Nutr 23: 447-456, 2004.
46. Selbie LA, Hill SJ. G protein-coupled-receptor cross-talk: the fine-tuning of multiple receptor-signalling pathways. Trends Pharmacol Sci 19: 87-93, 1998.
47. Shaw DI, Hall WL, Williams CM. Metabolic syndrome: what is it and what are the implications? Proc Nutr Soc 64: 349-357, 2005.
48. Shi S, Deng YZ, Zhao JS, Ji XD, Shi J, Feng YX, Li G, Li JJ, Zhu D, Koeffler HP, Zhao Y, Xie D. RACK1 promotes non-small-cell lung cancer tumorigenicity through activating sonic hedgehog signaling pathway. J Biol Chem 287: 7845-7858, 2012.
49. Sklan EH, Podoly E, Soreq H. RACK1 has the nerve to act: structure meets function in the nervous system. Prog Neurobiol 78: 117-134, 2006.
50. Song J, Rolfe BE, Campbell JH, Campbell GR. Changes in three-dimensional architecture of microfilaments in cultured vascular smooth muscle cells during phenotypic modulation. Tissue Cell 30: 324-333, 1998.
51. Stocks T, Van Hemelrijck M, Manjer J, Bjorge T, Ulmer H, Hallmans G, Lindkvist B, Selmer R, Nagel G, Tretli S, Concin H, Engeland A, Jonsson H, Stattin P. Blood pressure and risk of cancer incidence and mortality in the Metabolic Syndrome and Cancer Project. Hypertension 59: 802-810, 2012.
52. Strouch MB, Jackson EK, Mi Z, Metes NA, Carey GB. Extracellular cyclic AMP-adenosine pathway in isolated adipocytes and adipose tissue. Obes Res 13: 974-981, 2005.
53. Teixeira FV, Pera M, Kelly KA. Enhancing release of peptide YY after near-total proctocolectomy: jejunal pouch vs. ileal pouch-distal rectal anastomosis. J Gastrointest Surg 5: 108-112, 2001.
54. Thamilselvan V, Menon M, Thamilselvan S. Oxalate-induced activation of PKC-alpha and -delta regulates NADPH oxidase-mediated oxidative injury in renal tubular epithelial cells. Am J Physiol Renal Physiol 297: F1399-F1410, 2009.
55. 2+ regulation in human airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 298: L521-L530, 2010.
56. Trapasso F, Pichiorri F, Gaspari M, Palumbo T, Aqeilan RI, Gaudio E, Okumura H, Iuliano R, Di Leva G, Fabbri M, Birk DE, Raso C, Green-Church K, Spagnoli LG, Venuta S, Huebner K, Croce CM. Fhit interaction with ferredoxin reductase triggers generation of reactive oxygen species and apoptosis of cancer cells. J Biol Chem 283: 13736-13744, 2008.
57. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M, Narumiya S. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389: 990-994, 1997.
58. Velazquez-Garcia S, Valle S, Rosa TC, Takane KK, Demirci C, Alvarez-Perez JC, Mellado-Gil JM, Ernst S, Scott DK, Vasavada RC, Alonso LC, Garcia-Ocana A. Activation of protein kinase C-zeta in pancreatic (3-cells in vivo improves glucose tolerance and induces (3-cell expansion via mTOR activation. Diabetes 60: 2546-2559, 2011.
59. Vyas SJ, Mokkapatti R, Dubey RK, Chinoy MR, Jackson EK. Guanine nucleotide-binding inhibitory protein-mediated inhibition of adenylyl cyclase is enhanced in spontaneously hypertensive rat preglomerular arteriolar smooth muscle cells. J Pharmacol Exp Ther 285: 828-834, 1998.
60. Wang X, Yu W, Nawaz A, Guan F, Sun S, Wang C. Palmitate induced insulin resistance by PKCtheta-dependent activation of mTOR/S6K pathway in C2C12 myotubes. Exp Clin Endocrinol Diabetes 118: 657-661, 2010.
61. Wu X, Zhu M, Fletcher JA, Giobbie-Hurder A, Hodi FS. The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma. PLoS One 7: e29622, 2012.